Gillian M. Lamont

Publications by Year

Research Areas

PI3K/AKT/mTOR signaling in cancer, Cancer therapeutics and mechanisms, DNA Repair Mechanisms, Protein Kinase Regulation and GTPase Signaling, Catalytic Cross-Coupling Reactions

Most-Cited Works

• → Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor(2014)591 cited
• → AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity(2019)327 cited
• → Discovery of 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an Orally Bioavailable, Potent Inhibitor of Akt Kinases(2013)213 cited
• → The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor(2019)77 cited
• → Discovery of AZD4625, a Covalent Allosteric Inhibitor of the Mutant GTPase KRASG12C(2022)60 cited
• → Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of Monocarboxylate Transporter 4 (MCT4) for Oncology(2022)54 cited
• → Investigation of (E)-3-[4-(2-Oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic Acids as Oral Selective Estrogen Receptor Down-Regulators(2015)42 cited
• → Sulfonyl-morpholino-pyrimidines: SAR and development of a novel class of selective mTOR kinase inhibitor(2012)33 cited
• → Discovery of AZD4747, a Potent and Selective Inhibitor of Mutant GTPase KRASG12C with Demonstrable CNS Penetration(2023)31 cited
• → Optimization of Highly Kinase Selective Bis-anilino Pyrimidine PAK1 Inhibitors(2016)27 cited